Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2025, 169(3):218-225 | DOI: 10.5507/bp.2024.019

Comparison of the efficacy of cisplatin and carboplatin in combination with etoposide in firstline treatment of extensive-stage small cell lung cancer in real-world practice in the Czech Republic - a retrospective analysis of patients from the LUCAS project

Alzbeta Bejckova1, Miloslav Marel1, Zdenka Chladkova1, Libor Fila1, Luis Fernando Casas-Mendez1, Ondrej Venclicek2, Petr Jakubec3, Marketa Cernovska4, Michal Hrnciarik5, Jana Krejci6, Petr Domecky7, Martin Svaton8
1 Department of Pulmonology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
2 Department of Respiratory Diseases, Faculty of Medicine, Masaryk University and University Hospital, Brno, Czech Republic
3 Department of Respiratory Medicine, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
4 Department of Respiratory Medicine, Thomayer Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic
5 Pulmonary Department, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
6 Department of Pneumology, Bulovka University Hospital and 3rd Faculty of Medicine, Charles University, Prague, Czech Republic
7 OAKS Consulting Praha, Prague, Czech Republic
8 Department of Pneumology and Phthiseology, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic

Background: Patients with extensive-stage small-cell lung cancer (ES-SCLC) have a poor prognosis. The standard palliative treatment for four decades has been chemotherapy as a combination of etoposide with carboplatin or cisplatin, and in recent years, immunotherapy in addition.

Aims: To determine whether there is a difference in the efficacy of palliative chemotherapy as cisplatin or carboplatin in combination with etoposide in patients with ES-SCLC in real-world practice in the Czech Republic.

Methods: This was a retrospective analysis of a cohort of 348 patients from the LUCAS project with ES-SCLC. 79 were treated with etoposide plus cisplatin and 265 were treated with etoposide plus carboplatin. Kaplan-Meier curves and the Cox regression model were used for analysis.

Results: No statistically significant difference in median overall survival (mOS) or median progression free survival (mPFS) was found between groups or between patients grouped according to age and performance status (PS) in mOS. The Cox regression result was similar.

Conclusion: This study shows that cisplatin and carboplatin do not differ in efficacy in a given indication, thus when choosing a treatment, the physician should consider the expected toxicity in a particular patient, assessing the patient's general condition and comorbidities.

Keywords: small cell lung cancer, extensive-stage, carboplatin, cisplatin

Received: February 7, 2024; Revised: April 30, 2024; Accepted: May 30, 2024; Prepublished online: June 28, 2024; Published: September 19, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bejckova, A., Marel, M., Chladkova, Z., Fila, L., Casas-Mendez, L.F., Venclicek, O., ... Svaton, M. (2025). Comparison of the efficacy of cisplatin and carboplatin in combination with etoposide in firstline treatment of extensive-stage small cell lung cancer in real-world practice in the Czech Republic - a retrospective analysis of patients from the LUCAS project. Biomedical papers, 169(3), 218-225. doi: 10.5507/bp.2024.019
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. . Institute of Health Information and Statistics of the Czech Republic, Institute of Health Information and Statistics of the Czech Republic, Czech National Cancer Registry, [cited 2023 Jan 1] http://www.uzis.cz/registry-nzis/nor
    2. . Rodríguez-Martínez Á, Torres-Durán M, Barros-Dios JM, Ruano-Ravina A. Residential radon and small cell lung cancer. A systematic review. Cancer Lett 2018;426:57-62. Go to original source...
    3. . Torres-Durán M, Ruano-Ravina A, Kelsey KT, Parente-Lamelas I, Provencio M, Leiro-Fernández V, Abal-Arca J, Montero-Martínez C, Vidal-Garcia I, Pena C, Castro-Añón O, Golpe-Gómez A, Martínez C, Guzmán-Taveras R, Mejuto-Martí MJ, Fernández-Villar A, Barros-Dios JM. Small cell lung cancer in never-smokers. Eur Respir J 2016;47(3):947-53. doi: 10.1183/13993003.01524-2015 Go to original source... Go to PubMed...
    4. . Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, PiccirilloJ. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J ClinOncol 2006;24(28):4539-44. doi: 10.1200/JCO.2005.04.4859 Go to original source... Go to PubMed...
    5. . Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J 2010;35(1):202-15. doi: 10.1183/09031936.00105009 Go to original source... Go to PubMed...
    6. . Franco F, Carcereny E, Guirado M, Ortega AL, López-Castro R, Rodríguez-Abreu D, GarcíaCampelo R, DelBarco E, Juan O, Aparisi F, González-Larriba JL, Domine M, Trigo JM, Cobo M, Cerezo S, Calzas J, Massutí B, Bosch-Barrera J, GarcíaCoves P, Domènech M, Provencio M. Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry. PLoSOne 2021;16(6):e0251761. doi: 10.1371/journal.pone.0251761 Go to original source... Go to PubMed...
    7. . Johal S, Hettle R, Carroll J, Maguire P, Wynne T. Real-worldt reatment patterns and outcomes in small-cell lung cancer: a systematic literature review. J Thorac Dis 2021;13(6):3692-707. doi: 10.21037/jtd-20-3034 Go to original source... Go to PubMed...
    8. . Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, Crawford J, Randolph JA, Goodlow JL, Broun GO. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10(2):282-91. doi: 10.1200/JCO.1992.10.2.282 Go to original source... Go to PubMed...
    9. . Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV.; IMpower133 Study Group. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med 2018;379(23):2220-9. doi: 10.1056/NEJMoa1809064 Go to original source... Go to PubMed...
    10. . Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stagesmall-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019;394(10212):1929-39. doi: 10.1016/S0140-6736(19)32222-6 Go to original source... Go to PubMed...
    11. . Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, Keijser A, FaivreFinn C, Senan S. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 2015;385(9962):36-42. doi: 10.1016/S0140-6736(14)61085-0. Erratum in: Lancet 2015;385(9962):28. Go to original source... Go to PubMed...
    12. . Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365(5):395-409. doi: 10.1056/NEJMoa1102873 Go to original source... Go to PubMed...
    13. . du Bois A, Lück HJ, Meier W, Adams HP, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J; Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95(17):1320-9. doi: 10.1093/jnci/djg036 Go to original source... Go to PubMed...
    14. . Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21(17):3194-200 doi: 10.1200/JCO.2003.02.153. Corrected and republished in: J Clin Oncol 2023;41(25):4077-83. Go to original source... Go to PubMed...
    15. . Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: An analysis of the literature. Ann Oncol 1998;9:13-21. Go to original source...
    16. . Česká onkologická společnost. Modrá kniha České onkologické společnosti, 29. aktualizace. Brno: Masarykův onkologický ústav, 2023. ISBN 978-80-86793-55-9. www.linkos.cz/lekar-amultidisciplinarni-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/. In Czech
    17. . Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, Früh M, Qian W, Tamura T, Samantas E, Shibata T, Perrone F, Gallo C, Gridelli C, Martelli O, Lee SM. Carboplatin- or cisplatinbased chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 2012;30(14):1692-8. doi: 10.1200/JCO.2011.40.4905 Go to original source... Go to PubMed...
    18. . Azar I, Yazdanpanah O, Jang H, Austin A, Kim S, Chi J, Alkassis S, Saha BK, Chopra A, Neu K, Mehdi S, Mamdani H. Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans. JAMA Netw Open 2022;5(10):e2237699. doi: 10.1001/jamanetworkopen.2022.37699. Erratum in: JAMA Netw Open 2023;6(1):e2246257. Go to original source... Go to PubMed...
    19. . National Comprehensive Cancer Network. Small Cell Lung Cancer (Version 2.2024). https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed November 10, 2023.
    20. . Dingemans AC, Früh M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE, Lantuejoul S, Peters S, Reguart N, Rudin CM, De Ruysscher D, Van Schil PE, Vansteenkiste J, Reck M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol 2021;32(7):839-53. doi: 10.1016/j.annonc.2021.03.207 Go to original source... Go to PubMed...
    21. . Griesinger F, Korol EE, Kayaniyil S, Varol N, Ebner T, Goring SM. Efficacy and safety of firstline carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis. Lung Cancer 2019;135:196-204. doi: 10.1016/j.lungcan.2019.07.010 Go to original source... Go to PubMed...
    22. . Patatt FSA, Gonçalves LF, Paiva KM, Haas P. Ototoxic effects of antineoplastic drugs: a systematic review. Braz J Otorhinolaryngol 2022;88(1):130-40. doi: 10.1016/j.bjorl.2021.02.008 Go to original source... Go to PubMed...
    23. . McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf 1995;13(4):228-44. doi: 10.2165/00002018-199513040-00003 Go to original source... Go to PubMed...
    24. . Amptoulach S, Tsavaris N. Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Pract 2011;2011:843019. doi: 10.1155/2011/843019 Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content